Abstract
This article discusses innovations, advancements, and discoveries in continuous glucose monitoring (CGM) that were presented at the European Association for the Study of Diabetes 2024 Conference in Madrid, Spain, held in September 2024. Specifically, the author will discuss data from studies that discuss the impact of CGM on hemoglobin A1C in people with type 2 diabetes; the impact of CGM use in hospitalization settings for people with diabetes; the effectiveness of CGM in those who have undergone cardiac surgery; the efficacy of real-time CGM in adults hospitalized with diabetic ketoacidosis; time in rage in older individuals; and new devices for glucose sensing.